

Maximilian Christopeit

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9396501/publications.pdf>

Version: 2024-02-01

47
papers

1,156
citations

430754

18
h-index

414303

32
g-index

51
all docs

51
docs citations

51
times ranked

1879
citing authors

#	ARTICLE	IF	CITATIONS
1	Second Allograft for Hematologic Relapse of Acute Leukemia After First Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors: The Role of Donor Change. <i>Journal of Clinical Oncology</i> , 2013, 31, 3259-3271.	0.8	137
2	Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO). <i>Annals of Hematology</i> , 2014, 93, 1083-1095.	0.8	86
3	Diagnosis of invasive fungal diseases in haematology and oncology: 2018 update of the recommendations of the infectious diseases working party of the German society for hematology and medical oncology (<sc>AGIHO</sc>). <i>Mycoses</i> , 2018, 61, 796-813.	1.8	69
4	Community acquired respiratory virus infections in cancer patientsâ€”Guideline on diagnosis and management by the Infectious Diseases Working Party of the German Society for haematology and Medical Oncology. <i>European Journal of Cancer</i> , 2016, 67, 200-212.	1.3	66
5	Peritransplantation Ruxolitinib Prevents Acute Graft-versus-Host Disease in Patients with Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2152-2156.	2.0	65
6	Relative Impact of HLA Matching and Non-HLA Donor Characteristics on Outcomes of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2558-2567.	2.0	43
7	Treatment of invasive fungal diseases in cancer patientsâ€”Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). <i>Mycoses</i> , 2020, 63, 653-682.	1.8	42
8	Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e128-e140.	2.0	40
9	Comparison of clinical characteristics and disease outcome of COVID-19 and seasonal influenza. <i>Scientific Reports</i> , 2021, 11, 5803.	1.6	40
10	Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis. <i>European Journal of Haematology</i> , 2018, 101, 305-317.	1.1	39
11	Primary prophylaxis of bacterial infections and <i>Pneumocystis jirovecii</i> pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO). <i>Annals of Hematology</i> , 2021, 100, 1603-1620.	0.8	39
12	HSC commitmentâ€”associated epigenetic signature is prognostic in acute myeloid leukemia. <i>Journal of Clinical Investigation</i> , 2014, 124, 1158-1167.	3.9	38
13	Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous haematopoietic stem cell transplantation. 2020 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). <i>Annals of Hematology</i> , 2021, 100, 321-336.	0.8	34
14	Acute Myeloid Leukemia Stem Cells: The Challenges of Phenotypic Heterogeneity. <i>Cancers</i> , 2020, 12, 3742.	1.7	32
15	Comparison of immune reconstitution between anti-T-lymphocyte globulin and posttransplant cyclophosphamide as acute graft-versus-host disease prophylaxis in allogeneic myeloablative peripheral blood stem cell transplantation. <i>Haematologica</i> , 2022, 107, 857-867.	1.7	32
16	Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse. <i>Haematologica</i> , 2013, 98, 518-525.	1.7	31
17	A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation. <i>Blood Advances</i> , 2021, 5, 1760-1769.	2.5	22
18	Ruxolitinib plus extracorporeal photopheresis (ECP) for steroid refractory acute graft-versus-host disease of lower GI-tract after allogeneic stem cell transplantation leads to increased regulatory T cell level. <i>Bone Marrow Transplantation</i> , 2020, 55, 2286-2293.	1.3	22

#	ARTICLE	IF	CITATIONS
19	TKI Maintenance After Stem-Cell Transplantation for FLT3-ITD Positive Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 630429.	2.2	19
20	Vulnerability to reservoir reseeding due to high immune activation after allogeneic hematopoietic stem cell transplantation in individuals with HIV-1. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	17
21	Correlation of somatic mutations with outcome after FLAMSA–busulfan sequential conditioning and allogeneic stem cell transplantation in patients with myelodysplastic syndromes. <i>European Journal of Haematology</i> , 2016, 97, 288-296.	1.1	14
22	Central nervous system disorders after hematopoietic stem cell transplantation: a prospective study of the Infectious Diseases Working Party of EBMT. <i>Journal of Neurology</i> , 2020, 267, 430-439.	1.8	13
23	ABR, a novel inducer of transcription factor C/EBP™, contributes to myeloid differentiation and is a favorable prognostic factor in acute myeloid leukemia. <i>Oncotarget</i> , 2017, 8, 103626-103639.	0.8	13
24	Long-Term Survival Benefit after Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 95.e1-95.e4.	0.6	12
25	Role of pre–transplant MRD level detected by flow cytometry in recipients of allogeneic stem cell transplantation with AML. <i>European Journal of Haematology</i> , 2021, 106, 606-615.	1.1	12
26	Viral Dynamics of SARS-CoV-2 in Critically Ill Allogeneic Hematopoietic Stem Cell Transplant Recipients and Immunocompetent Patients with COVID-19. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 242-245.	2.5	12
27	Allogeneic stem cell transplantation for myelofibrosis patients aged ≥65 years. <i>European Journal of Haematology</i> , 2019, 103, 370-378.	1.1	11
28	Allogeneic stem cell transplantation following relapse post autologous stem cell transplantation in adult patients with acute myeloid leukemia: A retrospective analysis of 537 patients from the Acute Leukemia Working Party of the EBMT. <i>American Journal of Hematology</i> , 2018, 93, 1532-1542.	2.0	10
29	Treosulfan-Based Conditioning Regimen for Second Allograft in Patients with Myelofibrosis. <i>Cancers</i> , 2020, 12, 3098.	1.7	10
30	Relapse assessment following allogeneic SCT in patients with MDS and AML. <i>Annals of Hematology</i> , 2014, 93, 1097-1110.	0.8	9
31	Allogeneic stem cell transplantation in acute leukemia patients after COVID-19 infection. <i>Bone Marrow Transplantation</i> , 2021, 56, 1478-1481.	1.3	9
32	Multi-dimensional and longitudinal systems profiling reveals predictive pattern of severe COVID-19. <i>IScience</i> , 2021, 24, 102752.	1.9	9
33	Predicted Indirectly ReCognizable HLA Epitopes (PIRCHE) Are Associated with Poorer Outcome after Single Mismatch Unrelated Donor Stem Cell Transplantation: A Study of the Cooperative Transplant Study Group (KTS) of the German Group for Bone Marrow and Stem Cell Transplantation (DAG-KBT). <i>Transfusion Medicine and Hemotherapy</i> , 2019, 46, 370-375.	0.7	8
34	Monocenter study on epidemiology, outcomes, and risk factors of infections in recipients of 166 allogeneic stem cell transplantations during 1–year. <i>European Journal of Haematology</i> , 2020, 105, 126-137.	1.1	7
35	Allogeneic Stem Cell Transplantation for Patients with Lower-Risk Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2047-2052.	2.0	6
36	Digital-droplet PCR assays for IDH, DNMT3A and driver mutations to monitor after allogeneic stem cell transplantation minimal residual disease of myelofibrosis. <i>Bone Marrow Transplantation</i> , 2022, 57, 510-512.	1.3	6

#	ARTICLE	IF	CITATIONS
37	Major central nervous system complications after allogeneic stem cell transplantation: A large retrospective study on 888 consecutive adult patients. <i>European Journal of Haematology</i> , 2020, 105, 722-730.	1.1	5
38	Ruxolitinib during Peritransplant Period for Myelofibrosis Patients Undergoing Allogeneic Stem Cell Transplantation Reduces Acute Graft-Versus-Host Disease. <i>Blood</i> , 2016, 128, 2242-2242.	0.6	5
39	Detection of human herpes virus 6 DNA and chromosomal integration after allogeneic hematopoietic stem cell transplantation: a retrospective single center analysis. <i>Transplant Infectious Disease</i> , 2022, , .	0.7	5
40	Acute hepatitis as a prequel to very severe aplastic anemia. <i>Zeitschrift Fur Gastroenterologie</i> , 2018, 56, 51-54.	0.2	4
41	Incidence and Outcome of Late Relapse after Allogeneic Stem Cell Transplantation for Myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2279-2284.	2.0	4
42	Post-transplant MFC-MRD status on day +100 predicts outcomes for refractory AML patients.. <i>Transplantation and Cellular Therapy</i> , 2022, , .	0.6	3
43	Scabies crustosa in a recipient of an allogeneic stem cell transplantation. <i>Infection</i> , 2021, 49, 375-376.	2.3	2
44	Second allogeneic stem cell transplantation for relapse after allografting in multiple myeloma using CD 34+ selected donor cells without immunosuppression. <i>Bone Marrow Transplantation</i> , 2020, 55, 1817-1820.	1.3	1
45	Impact of Donor-Recipient Histocompatibility and CMV-Mismatch on Outcome of Allogeneic Stem Cell Transplantation for AML and MDS: A Retrospective Registry Study of the German Stem Cell Transplant Registry (DRST) of the German Working Group for Blood and Marrow Transplantation (DAG-KBT). <i>Blood</i> , 2016, 128, 2304-2304.	0.6	1
46	Clonal Evolution after Allogeneic Hematopoietic Stem Cell Transplantation: The Case of Myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e167-e170.	2.0	0
47	â€žPer aspera ad astraâ€œ! die Facharztzeitschrift. <i>Onkologie</i> , 2021, 27, 2-4.	0.7	0